Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

Authors: Aleix Prat, Cristina Saura, Tomás Pascual, Cristina Hernándo, Montserrat Muñoz-Mateu, Laia Paré, Blanca González‐Farré, Pedro L. Fernández, Patricia Galván, Núria Chic, Xavier González, Mafalda Oliveira, Miguel Gil‐Gil, Míriam Arumí, Neus Ferrer, Álvaro Montaño, Yann Izarzugaza, Antonio Llombart‐Cussac, Raquel Bratos, Santiago González Santiago, Eduardo Martínez de Dueñas, Sergio Hoyos, Beatriz Rojas, Juan Antonio Virizuela, Vanesa Ortega, Rafael López‐López, P. Céliz, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá - The Lancet 2019 cited by 201